Physician profile
Jeffrey E Wong
NPI 1730167818
$3,185.20
in general payments reported to CMS, 2019-2025
24 companies · $781 in 2025
The $781 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $151 · 2021: $462 · 2022: $423 · 2023: $333 · 2024: $306 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,419.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $978.54 | 2021-2023 | Urolift |
| Calyxo, INC. | $384.25 | 2024-2025 | Cvac Aspiration System |
| Astellas Pharma US INC | $314.27 | 2019-2023 | Myrbetriq |
| Laborie Medical Technologies Corp. | $293.76 | 2024-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Janssen Biotech, INC. | $161.48 | 2019-2025 | Erleada |
| Pfizer INC. | $152.19 | 2019-2025 | |
| Bioprotect Medical, INC. | $135.68 | 2024 | Bioprotect Balloon Implant System |
| Boston Scientific Corporation | $131.21 | 2019 | |
| Olympus America INC. | $125.09 | 2023-2025 | Itind System |
| Endo Pharmaceuticals INC. | $97.57 | 2019-2022 | |
| Neotract INC. | $70.72 | 2020 | |
| Procept Biorobotics Corporation | $55.65 | 2021 | |
| Rochester Medical Corporation | $55.50 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $45.56 | 2019 | |
| Sun Pharmaceutical Industries INC. | $26.91 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $24.44 | 2025 | Gazyva |
| Allergan, INC. | $22.28 | 2019 | |
| Dendreon Pharmaceuticals LLC | $22.15 | 2020 | |
| Accord Healthcare, INC. | $17.67 | 2022 | |
| Metuchen Pharmaceuticals | $17.59 | 2019 | |
| Immunitybio, INC. | $14.99 | 2025 | |
| Myriad Genetic Laboratories, INC. | $14.43 | 2023 | Prolaris |
| Zyla Life Sciences, INC. | $11.67 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.